Today: The Sarepta Therapeutics Inc. (SRPT) Given a $68.00 Price Target by Piper Jaffray Cos. Analysts

The Sarepta Therapeutics Inc. (SRPT) Given a $68.00 Price Target by Piper Jaffray Cos. Analysts

Piper Jaffray Cos. set a $68.00 price objective on Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note released on Tuesday morning. The brokerage currently has a a buy rating on the stock.

SRPT has been the topic of several other research reports. JMP Securities raised Sarepta Therapeutics to an outperform rating and boosted their price target for the company from $10.00 to $60.00 in a research note on Monday, September 19th. Royal Bank Of Canada raised Sarepta Therapeutics from a sector perform rating to an outperform rating and set a $83.00 price target on the stock in a research note on Monday, September 19th. Leerink Swann reaffirmed an underperform rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 4th. Robert W. Baird reaffirmed an outperform rating and issued a $102.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 30th. Finally, Oppenheimer Holdings Inc. reaffirmed an outperform rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, July 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $58.12.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 57.89 on Tuesday. The company’s 50 day moving average price is $40.98 and its 200 day moving average price is $25.39. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73. The firm’s market capitalization is $2.77 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the business earned ($0.87) earnings per share. Analysts forecast that Sarepta Therapeutics will post ($4.23) earnings per share for the current year.

In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 40,179 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $2,410,740.00. Following the completion of the transaction, the chief executive officer now directly owns 117,162 shares of the company’s stock, valued at $7,029,720. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP David T. Howton sold 7,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $420,000.00. Following the completion of the transaction, the senior vice president now directly owns 28,453 shares of the company’s stock, valued at $1,707,180. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. National Planning Corp boosted its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the last quarter. Rhumbline Advisers boosted its position in Sarepta Therapeutics by 1.6% in the second quarter. Rhumbline Advisers now owns 46,719 shares of the company’s stock worth $891,000 after buying an additional 721 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the last quarter. First Allied Advisory Services Inc. boosted its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the last quarter. Finally, LGL Partners LLC boosted its position in Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock valued at $485,000 after buying an additional 1,000 shares in the last quarter. 65.29% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Related posts

Leave a Comment